Obsidian Therapeutics (OBX) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical business developing engineered tumor-infiltrating lymphocyte (TIL) therapies for solid tumors using the cytoDRIVE protein-regulation platform; lead candidate amsoki-cel is autologous and uses regulatable membrane-bound IL15.

• Amsoki-cel is in Phase 2 for advanced melanoma and Phase 1 for NSCLC; the platform is also being explored for other cell and gene therapy applications.

• The candidate uses acetazolamide to regulate IL15 expression, aims to avoid IL2 dosing, and enables low-dose lymphodepletion and outpatient core-needle tumor procurement.

• Worldwide rights are held to amsoki-cel and earlier-stage candidates; U.S. commercialization is planned internally, with potential partnerships in other regions.

Financial performance and metrics

• No product-sales revenue to date; historical revenue came from collaboration and license agreements that have expired or concluded.

• Net loss was $45.5M for H1 2026 vs. $51.9M H1 2025; FY2025 net loss was $100.6M vs. $83.1M FY2024.

• Cash, cash equivalents and marketable securities totaled $34.4M at June 30, 2026; H1 2026 operating cash use was $47.3M.

• The $350M gross PIPE closed July 31, 2026; combined with existing liquidity, net proceeds were expected to fund operations into H2 2028.

• Accumulated deficit was $341.4M at June 30, 2026; losses and negative operating cash flows are expected to continue as clinical development advances.

Use of proceeds and capital allocation

• No proceeds from the registered resales will go to the issuer; selling holders bear their brokerage, legal, accounting, tax and other disposal costs.

• Registration costs are borne by the issuer, excluding selling-holder underwriting discounts, commissions and transfer taxes.

• PIPE proceeds support planned operations and continued clinical development; R&D spending is expected to rise as trials, manufacturing, regulatory work and commercial preparation progress.